Effect of Maternal Docosahexaenoic Acid Supplementation on Very Preterm Infant Growth: Secondary Outcome of a Randomized Clinical Trial

Georgina Angoa; Etienne Pronovost; Aissatou Bintou Khairy Thilor Ndiaye; Pascal M. Lavoie; Brigitte Lemyre; Ibrahim Mohamed; David Simonyan; Mosarrat Qureshi; Jehier Afifi; Kamran Yusuf; Thibaut Sériès; Mireille Guillot; Bruno Piedboeuf; William Donald Fraser; Anne Monique Nuyt; Benoît Mâsse; Thierry Lacaze-Masmonteil; Isabelle Marc

doi:10.1159/000524147

Effect of Maternal Docosahexaenoic Acid Supplementation on Very Preterm Infant Growth: Secondary Outcome of a Randomized Clinical Trial

Georgina Angoa, Etienne Pronovost, Aissatou Bintou Khairy Thilor Ndiaye, Pascal M. Lavoie, Brigitte Lemyre, Ibrahim Mohamed, David Simonyan, Mosarrat Qureshi, Jehier Afifi, Kamran Yusuf, Thibaut Sériès, Mireille Guillot, Bruno Piedboeuf, William Donald Fraser, Anne Monique Nuyt, Benoît Mâsse, Thierry Lacaze-Masmonteil, Isabelle Marc

Medicine

Résultat de recherche: Article › examen par les pairs

4 Citations (Scopus)

Résumé

Introduction: The aim of the study was to determine the effect of a maternal docosahexaenoic acid (DHA) supplementation during lactation, compared with a placebo, on the neonatal growth profile of breastfed very preterm infants. Methods: Preterm infants' growth profile, growth velocity from birth to 36 weeks' postmenstrual age (PMA), and growth at 36 weeks' PMA were pre-specified secondary outcomes of a randomized placebo-controlled trial conducted in 16 Canadian neonatal intensive care units (2015-2018). Lactating mothers who delivered before 29 weeks' gestation were given 1.2 g of DHA daily or a placebo within 72 h of delivery and up to 36 weeks' PMA. Analyses were performed using a linear regression model with generalized estimating equations. Results: 461 mothers and their 528 infants (DHA, N = 273; placebo, N = 255) were included with mean gestational age of 26.5 weeks (standard deviation [SD] = 1.6); 275 (52.1%) were males; mean birth weight was 895 g (SD = 240). DHA interaction with sex was significant on weight profile (interaction p < 0.001), weight velocity (interaction p = 0.05), and weight at 36 weeks' PMA (interaction p = 0.02). Females in the DHA group gained more weight compared to the placebo group (mean difference [MD], 52.6 g [95% confidence interval [CI]: 24.5-80.8], p < 0.001). Weight velocity was significantly higher in females of the DHA group (MD, 3.4 g/kg/day [95% CI: 0.6-6.2], p = 0.02). At 36 weeks' PMA, the weight of males in the DHA group was significantly smaller (MD, -88.9 g [95% CI: -166.2 to -11.6], p = 0.02). Conclusion: DHA positively affected female infants' neonatal weight profile and velocity and negatively affected male infants' weight at 36 weeks' PMA.

Langue d'origine	English
Pages (de-à)	377-385
Nombre de pages	9
Journal	Neonatology
Volume	119
Numéro de publication	3
DOI	https://doi.org/10.1159/000524147
Statut de publication	Published - mai 1 2022

Note bibliographique

Funding Information:
The docosahexaenoic acid and placebo capsules were provided in-kind by DSM Nutritional Products. The MOBYDIck trial was funded by grant MOP-136964 from the Canadian Institutes of Health Research (CIHR), grant 2598 from the Fondation du CHU de Québec, and the Fonds d’approche Intégrée en Santé des Femmes (Université Laval). Isabelle Marc was the recipient of a senior clinician research fellowship (No. 32933) from the Fonds de la Recherche en Santé du Québec. Pascal M. Lavoie was the recipient of investigator awards from the BC Children’s Hospital Research Institute and the Michael Smith Foundation for Health Research. The funders/sponsors had no role in the design and conduct of the study or the preparation of the manuscript.

Publisher Copyright:
© 2022

ASJC Scopus Subject Areas

Pediatrics, Perinatology, and Child Health
Developmental Biology

PubMed: MeSH publication types

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Accès au document

10.1159/000524147

Autres fichiers et liens

Citer

Angoa, G., Pronovost, E., Ndiaye, A. B. K. T., Lavoie, P. M., Lemyre, B., Mohamed, I., Simonyan, D., Qureshi, M., Afifi, J., Yusuf, K., Sériès, T., Guillot, M., Piedboeuf, B., Fraser, W. D., Nuyt, A. M., Mâsse, B., Lacaze-Masmonteil, T., & Marc, I. (2022). Effect of Maternal Docosahexaenoic Acid Supplementation on Very Preterm Infant Growth: Secondary Outcome of a Randomized Clinical Trial. Neonatology, 119(3), 377-385. https://doi.org/10.1159/000524147

Angoa, G, Pronovost, E, Ndiaye, ABKT, Lavoie, PM, Lemyre, B, Mohamed, I, Simonyan, D, Qureshi, M, Afifi, J, Yusuf, K, Sériès, T, Guillot, M, Piedboeuf, B, Fraser, WD, Nuyt, AM, Mâsse, B, Lacaze-Masmonteil, T & Marc, I 2022, 'Effect of Maternal Docosahexaenoic Acid Supplementation on Very Preterm Infant Growth: Secondary Outcome of a Randomized Clinical Trial', Neonatology, vol. 119, n° 3, pp. 377-385. https://doi.org/10.1159/000524147

@article{f6b71893282743a095a05e777268ce8b,

title = "Effect of Maternal Docosahexaenoic Acid Supplementation on Very Preterm Infant Growth: Secondary Outcome of a Randomized Clinical Trial",

abstract = "Introduction: The aim of the study was to determine the effect of a maternal docosahexaenoic acid (DHA) supplementation during lactation, compared with a placebo, on the neonatal growth profile of breastfed very preterm infants. Methods: Preterm infants' growth profile, growth velocity from birth to 36 weeks' postmenstrual age (PMA), and growth at 36 weeks' PMA were pre-specified secondary outcomes of a randomized placebo-controlled trial conducted in 16 Canadian neonatal intensive care units (2015-2018). Lactating mothers who delivered before 29 weeks' gestation were given 1.2 g of DHA daily or a placebo within 72 h of delivery and up to 36 weeks' PMA. Analyses were performed using a linear regression model with generalized estimating equations. Results: 461 mothers and their 528 infants (DHA, N = 273; placebo, N = 255) were included with mean gestational age of 26.5 weeks (standard deviation [SD] = 1.6); 275 (52.1%) were males; mean birth weight was 895 g (SD = 240). DHA interaction with sex was significant on weight profile (interaction p < 0.001), weight velocity (interaction p = 0.05), and weight at 36 weeks' PMA (interaction p = 0.02). Females in the DHA group gained more weight compared to the placebo group (mean difference [MD], 52.6 g [95% confidence interval [CI]: 24.5-80.8], p < 0.001). Weight velocity was significantly higher in females of the DHA group (MD, 3.4 g/kg/day [95% CI: 0.6-6.2], p = 0.02). At 36 weeks' PMA, the weight of males in the DHA group was significantly smaller (MD, -88.9 g [95% CI: -166.2 to -11.6], p = 0.02). Conclusion: DHA positively affected female infants' neonatal weight profile and velocity and negatively affected male infants' weight at 36 weeks' PMA. ",

author = "Georgina Angoa and Etienne Pronovost and Ndiaye, {Aissatou Bintou Khairy Thilor} and Lavoie, {Pascal M.} and Brigitte Lemyre and Ibrahim Mohamed and David Simonyan and Mosarrat Qureshi and Jehier Afifi and Kamran Yusuf and Thibaut S{\'e}ri{\`e}s and Mireille Guillot and Bruno Piedboeuf and Fraser, {William Donald} and Nuyt, {Anne Monique} and Beno{\^i}t M{\^a}sse and Thierry Lacaze-Masmonteil and Isabelle Marc",

note = "Funding Information: The docosahexaenoic acid and placebo capsules were provided in-kind by DSM Nutritional Products. The MOBYDIck trial was funded by grant MOP-136964 from the Canadian Institutes of Health Research (CIHR), grant 2598 from the Fondation du CHU de Qu{\'e}bec, and the Fonds d{\textquoteright}approche Int{\'e}gr{\'e}e en Sant{\'e} des Femmes (Universit{\'e} Laval). Isabelle Marc was the recipient of a senior clinician research fellowship (No. 32933) from the Fonds de la Recherche en Sant{\'e} du Qu{\'e}bec. Pascal M. Lavoie was the recipient of investigator awards from the BC Children{\textquoteright}s Hospital Research Institute and the Michael Smith Foundation for Health Research. The funders/sponsors had no role in the design and conduct of the study or the preparation of the manuscript. Publisher Copyright: {\textcopyright} 2022 ",

year = "2022",

month = may,

day = "1",

doi = "10.1159/000524147",

language = "English",

volume = "119",

pages = "377--385",

journal = "Neonatology",

issn = "1661-7800",

publisher = "S. Karger AG",

number = "3",

}

TY - JOUR

T1 - Effect of Maternal Docosahexaenoic Acid Supplementation on Very Preterm Infant Growth

T2 - Secondary Outcome of a Randomized Clinical Trial

AU - Angoa, Georgina

AU - Pronovost, Etienne

AU - Ndiaye, Aissatou Bintou Khairy Thilor

AU - Lavoie, Pascal M.

AU - Lemyre, Brigitte

AU - Mohamed, Ibrahim

AU - Simonyan, David

AU - Qureshi, Mosarrat

AU - Afifi, Jehier

AU - Yusuf, Kamran

AU - Sériès, Thibaut

AU - Guillot, Mireille

AU - Piedboeuf, Bruno

AU - Fraser, William Donald

AU - Nuyt, Anne Monique

AU - Mâsse, Benoît

AU - Lacaze-Masmonteil, Thierry

AU - Marc, Isabelle

N1 - Funding Information: The docosahexaenoic acid and placebo capsules were provided in-kind by DSM Nutritional Products. The MOBYDIck trial was funded by grant MOP-136964 from the Canadian Institutes of Health Research (CIHR), grant 2598 from the Fondation du CHU de Québec, and the Fonds d’approche Intégrée en Santé des Femmes (Université Laval). Isabelle Marc was the recipient of a senior clinician research fellowship (No. 32933) from the Fonds de la Recherche en Santé du Québec. Pascal M. Lavoie was the recipient of investigator awards from the BC Children’s Hospital Research Institute and the Michael Smith Foundation for Health Research. The funders/sponsors had no role in the design and conduct of the study or the preparation of the manuscript. Publisher Copyright: © 2022

PY - 2022/5/1

Y1 - 2022/5/1

N2 - Introduction: The aim of the study was to determine the effect of a maternal docosahexaenoic acid (DHA) supplementation during lactation, compared with a placebo, on the neonatal growth profile of breastfed very preterm infants. Methods: Preterm infants' growth profile, growth velocity from birth to 36 weeks' postmenstrual age (PMA), and growth at 36 weeks' PMA were pre-specified secondary outcomes of a randomized placebo-controlled trial conducted in 16 Canadian neonatal intensive care units (2015-2018). Lactating mothers who delivered before 29 weeks' gestation were given 1.2 g of DHA daily or a placebo within 72 h of delivery and up to 36 weeks' PMA. Analyses were performed using a linear regression model with generalized estimating equations. Results: 461 mothers and their 528 infants (DHA, N = 273; placebo, N = 255) were included with mean gestational age of 26.5 weeks (standard deviation [SD] = 1.6); 275 (52.1%) were males; mean birth weight was 895 g (SD = 240). DHA interaction with sex was significant on weight profile (interaction p < 0.001), weight velocity (interaction p = 0.05), and weight at 36 weeks' PMA (interaction p = 0.02). Females in the DHA group gained more weight compared to the placebo group (mean difference [MD], 52.6 g [95% confidence interval [CI]: 24.5-80.8], p < 0.001). Weight velocity was significantly higher in females of the DHA group (MD, 3.4 g/kg/day [95% CI: 0.6-6.2], p = 0.02). At 36 weeks' PMA, the weight of males in the DHA group was significantly smaller (MD, -88.9 g [95% CI: -166.2 to -11.6], p = 0.02). Conclusion: DHA positively affected female infants' neonatal weight profile and velocity and negatively affected male infants' weight at 36 weeks' PMA.

AB - Introduction: The aim of the study was to determine the effect of a maternal docosahexaenoic acid (DHA) supplementation during lactation, compared with a placebo, on the neonatal growth profile of breastfed very preterm infants. Methods: Preterm infants' growth profile, growth velocity from birth to 36 weeks' postmenstrual age (PMA), and growth at 36 weeks' PMA were pre-specified secondary outcomes of a randomized placebo-controlled trial conducted in 16 Canadian neonatal intensive care units (2015-2018). Lactating mothers who delivered before 29 weeks' gestation were given 1.2 g of DHA daily or a placebo within 72 h of delivery and up to 36 weeks' PMA. Analyses were performed using a linear regression model with generalized estimating equations. Results: 461 mothers and their 528 infants (DHA, N = 273; placebo, N = 255) were included with mean gestational age of 26.5 weeks (standard deviation [SD] = 1.6); 275 (52.1%) were males; mean birth weight was 895 g (SD = 240). DHA interaction with sex was significant on weight profile (interaction p < 0.001), weight velocity (interaction p = 0.05), and weight at 36 weeks' PMA (interaction p = 0.02). Females in the DHA group gained more weight compared to the placebo group (mean difference [MD], 52.6 g [95% confidence interval [CI]: 24.5-80.8], p < 0.001). Weight velocity was significantly higher in females of the DHA group (MD, 3.4 g/kg/day [95% CI: 0.6-6.2], p = 0.02). At 36 weeks' PMA, the weight of males in the DHA group was significantly smaller (MD, -88.9 g [95% CI: -166.2 to -11.6], p = 0.02). Conclusion: DHA positively affected female infants' neonatal weight profile and velocity and negatively affected male infants' weight at 36 weeks' PMA.

UR - http://www.scopus.com/inward/record.url?scp=85129318054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129318054&partnerID=8YFLogxK

U2 - 10.1159/000524147

DO - 10.1159/000524147

M3 - Article

C2 - 35413719

AN - SCOPUS:85129318054

SN - 1661-7800

VL - 119

SP - 377

EP - 385

JO - Neonatology

JF - Neonatology

IS - 3

ER -

Effect of Maternal Docosahexaenoic Acid Supplementation on Very Preterm Infant Growth: Secondary Outcome of a Randomized Clinical Trial

Résumé

Note bibliographique

ASJC Scopus Subject Areas

PubMed: MeSH publication types

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer